Vnitřní lékařství 7/2020

PŘEHLEDOVÉ ČLÁNKY Kostní metabolismus u idiopatických střevních zánětů 1 | E7  / Vnitř Lék 2020; 66(7): e3–e7 /  VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 54. Devogelaer JP. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 2007; 32: 733–757. 55. Canalis E, Mazziotti G, Giustina A, et al. Glucorticoid-induced osteoporosis: pathophys- iology and therapy. Osteoporos Int 2007; 18: 1319–1328. 56. Tan B, Li P, Lv H, et al. Vitamin D and BMD in Chinese IBD patients. Journal of Digesti- ve Diseases 2014; 15: 116–123. 57. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with os- teoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896–904. 58. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroen- terol 2011; 106: 1209–1218. 59. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calci- um absorption? J Bone Miner Res 2010; 25: 786–795. 60. Sgambato D, Gimigliano F, De Musis C, et al. Bone alterations in inflammatory bowel diseases. World J Clin Cases 2019; 7: 1908–1925.